In contrast, similar expression levels of MTTP and apoB100 between patients with steatosis, NASH, and healthy controls have also been reported, denoting the considerable disease heterogeneity associated with NAFLD [124]. This evidence concerns the gene MTTP and metabolic dysfunction-associated steatohepatitis.